

NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations

Item 1 Names of the Parties to the Transaction

Aura Health Inc. (formerly, Lamelee Iron Ore Ltd.) (the "**Corporation**") and Aura Health Corp. ("**Aura**").

Item 2 Description of the Transaction

The Corporation completed its previously announced acquisition (the "**Acquisition**") of all of the issued and outstanding securities of Aura. Aura is a Toronto based company that has investments in four operating medical marijuana patient assessment clinics in Arizona, Nevada and Florida.

As a result of the Acquisition, Aura became a wholly owned subsidiary of the Corporation. The Acquisition constituted a reverse take-over of the Corporation by Aura.

In connection with the Acquisition, the following principal matters, among others, were completed:

- (a) the Corporation continued from *Canada Business Corporations Act* to the *Business Corporations Act* (Ontario) (the "**Continuance**");
- (b) the Corporation voluntarily delisted its common shares from the TSXV Venture Exchange on August 8, 2018 (the "**TSXV Delisting**") and listed its common shares on the Canadian Securities Exchange (the "**CSE**") on August 16, 2018;
- (c) as consideration for the Acquisition of all of the issued and outstanding securities of Aura, the Corporation issued the following securities:
 - (i) a total of 20,048,200 common shares;
 - (ii) a total of 5,985,037 warrants of the Corporation ("**Replacement Warrants**"), each Replacement Warrant exercisable to purchase one common share until August 9, 2020 at an exercise price of \$0.15 for 3,275,000 Replacement Warrants, \$0.75 for 2,301,873 Replacement Warrants and \$1.00 for 408,164 Replacement Warrants;
 - (iii) a replacement secured convertible note for the principal amount of US\$120,000 due November 14, 2018, convertible into units at \$0.05 per unit of November 14, 2018, with each unit comprised of one common share and 1/2 of a warrant, with each whole warrant to purchase one additional common share at \$0.075 until August 9, 2020;
 - (iv) replacement Series B convertible debentures in aggregate principal amount of C\$600,000 due December 22, 2019, convertible into common shares at \$0.3675 until December 22, 2019;

- (v) 20,000 replacement broker warrants of the Corporation each exercisable to purchase one common share at \$1.00 per share until April 20, 2019;
 - (vi) 80,000 replacement finder warrants of the Corporation each exercisable to purchase one common share at \$0.60 per share until December 22, 2019;
 - (vii) a total of 500,000 replacement compensation options of the Corporation each exercisable into one units until August 9, 2020 at \$0.10 per unit, with each unit comprised of one common share and ½ of a warrant, with each whole warrant to purchase one additional common share at \$0.15 until August 9, 2020;
 - (viii) a total of 70,785 replacement finder options of the Corporation each exercisable into one units at \$0.49 per unit until August 9, 2020, with each unit comprised of one common share and one warrant, with each warrant to purchase one additional common share at \$0.75 until August 9, 2020; and
 - (ix) a total of 1,600,000 replacement stock options, exercisable at \$0.10 per share until August 9, 2020.
- (d) the Corporation changed its name from Lamelee Iron Ore Ltd. to Aura Health Inc. (the "**Name Change**");
 - (e) the Corporation changed its financial year-end from September 30 to December 31 in order to match the financial year-end of Aura;
 - (f) the Corporation changed its auditors to MNP LLP, Aura's auditors;
 - (g) the Corporation issued 300,000 common shares on closing of the Transaction to a finder of the Corporation with respect to the Acquisition.

The Corporation's shareholders approved the Continuance, the TSXV Delisting and the Name Change at the annual and special meeting of the Corporation's shareholders held on April 4, 2018.

Item 3 Effective Date of the Transactions

The effective date of the Continuance, Name Change and Acquisition is August 9, 2018.

Item 4 Name of Each Party, if any, that Ceased to be a Reporting Issuer Subsequent to the Transaction and of each Continuing Entity

The Corporation will continue to be a reporting issuer in British Columbia, Alberta, Manitoba, Ontario and Quebec, and the Corporation's common shares recommenced trading on the Canadian Securities Exchange under the symbol BUZZ on August 16, 2018.

Item 5 Date of the Reporting Issuer's First Financial Year-End Subsequent to the Transaction

The financial year-end of Aura is December 31. The Corporation changed its financial year-end from September 30 to December 31 subsequent to the closing of the Acquisition in order to match the financial year-end of Aura. Therefore, the first financial year-end of the Corporation subsequent to the Acquisition is December 31, 2018.

Item 6 Periods, Including Comparative Periods, if any, of the Interim and Annual Financial Statements Required to be Filed for the Company's First Financial Year Subsequent to the Transaction

The Corporation is not required to file audited annual financial statements of the Corporation for the twelve months ended September 30, 2018.

With respect to financial periods of Aura ending prior to the completion of the Acquisition for which financial statements have not previously been filed, the Corporation is required to file:

- unaudited interim consolidated financial statements of Aura for the 3 and 6 months period ended June 30, 2018, with comparative period information for the 3 and 6 months period of Aura ended June 30, 2017, which financial statements are required to be filed by August 29, 2018; and
- unaudited interim combined joint venture financial statements of the four Sun Valley medical marijuana assessment clinics in which Aura holds a minority interest (the "**Sun Valley Clinics**") for the 3 and 6 months period ended June 30, 2018, with comparative period information for the 3 and 6 months period of Aura ended June 30, 2017, which financial statements are required to be filed by August 29, 2018;

With respect to financial periods in the Corporation's first financial year subsequent to the completion of the Acquisition, the Corporation is required to file:

- unaudited interim consolidated financial statements of the Corporation for the 3 and 9 months period ended September 30, 2018, with comparative period information for the 3 and 9 months period of Aura ended September 30, 2017, which financial statements are required to be filed by November 29, 2018; and
- audited annual consolidated financial statements of the Corporation for the 12 month period ended December 31, 2018, with comparative period information for the 12 month period of Aura ended December 31, 2017, which financial statements are required to be filed by April 30, 2019.
- if the Corporation's investment in the Sun Valley Clinics represents in the aggregate, a significant asset of the Corporation, the Corporation will file audited annual financial statements and unaudited interim financial statements for the Sun Valley Clinics at the same time as the Corporation's financial statements filings.

Item 7 Documents Filed under NI 51-102 that describe the Transaction and where they can be found in electronic format

The Acquisition is described in the Corporation's amended and restated listing statement dated July 31, 2018 and in the Corporation's press release dated August 10, 2018 and material change report dated August 16, 2018, which can be found on SEDAR at www.sedar.com.

Dated: August 24, 2018.